Text Marked By [* * *] Has Been Omitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities And Exchange Commission. PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • August 15th, 2011 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations • Texas
This thirty-nine (39) page AGREEMENT (“AGREEMENT”) is made on this 11th day of September, 2006, by and between: (1) THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a component institution of SYSTEM; (2) THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (“HJF”), a Maryland tax-exempt corporation, whose address is 1401 Rockville Pike, Suite 600, Rockville Maryland 20852, on its own behalf and on behalf of THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES (“USU”), an institution of higher learning within the Department of Defense, an agency of the United States Government, located at 4301 Jones Bridge Road, Bethesda, Maryland 20814-4779; and (3) ADVANCED PEPTIDE THERAPEUTICS, INC., a Delaware corporation having a principal place of business located at 9450
RXI PHARMACEUTICALS CORPORATION SCIENTIFIC ADVISORY AGREEMENTScientific Advisory Agreement • August 15th, 2011 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
This Scientific Advisory Agreement (the “Agreement”) dated as of April 13, 2011, is made by Dr. George E. Peoples (the “Advisor”) and RXi Pharmaceuticals Corporation, a Delaware corporation (“RXi” and together with the Advisor, the “Parties”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 15th, 2011 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
The Employment Agreement (the “Agreement”) is made and entered into as of April 13, 2011 (the “Effective Date”) by and between RXi Pharmaceuticals Corporation, a Delaware corporation (the “Company”, or “Employer”), and Mark W. Schwartz, Ph.D., an individual and resident of the State of California (“Employee”).
Text Marked By [* * *] Has Been Omitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities And Exchange Commission. EXCLUSIVE LICENSE AGREEMENT BETWEEN THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF...Exclusive License Agreement • August 15th, 2011 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations • Maryland
THIS EXCLUSIVE LICENSE AGREEMENT (“Agreement”) is entered into as of the date of the last signature on the signature page of this document (the “Effective Date”), by and among The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., a tax-exempt corporation organized under the laws of the State of Maryland and having its principal offices at 1401 Rockville Pike, Suite 600, Rockville, Maryland 20852 (the “Foundation”) and RXi Pharmaceuticals Corporation (“RXi”), a corporation organized under the laws of the State of Delaware and having its principal offices at 60 Prescott Street, Worcester, MA 01605 and its wholly-owned subsidiary, Apthera, Inc. (“Apthera”). This Agreement grants a license that can be exploited by either or both of RXi and Apthera, and RXi and Apthera are referred to both individually and collectively throughout as “Licensee” but any termination of this Agreement with respect to either of RXi or Apthera shall terminate this Agreement as to both RX
AMENDMENT NO. 1 TO THE PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • August 15th, 2011 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations
This AMENDMENT NO. 1 to the Exclusive PATENT AND TECHNOLOGY LICENSE AGREEMENT between the PARTIES dated September 11, 2006 (“ORIGINAL LICENSE”), effective the 21st day of December, 2007 (which is the date this AMENDMENT NO. 1 has been fully executed by all PARTIES), is made by and between: (1) THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a component institution of SYSTEM; (2) THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (“HJF”), a Maryland tax-exempt corporation, whose address is 140 1 Rockville Pike, Suite 600, Rockville, Maryland 20852, on its own behalf and on behalf of THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES (“USU”), an institution of higher learning within the Department of Defense, an agency of the United States Government, locate
AMENDMENT NO. 2 TO THE PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • August 15th, 2011 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations
This AMENDMENT NO. 2 to the Exclusive PATENT AND TECHNOLOGY LICENSE AGREEMENT between the PARTIES dated September 11, 2006, as amended on December 21, 2007 (the “LICENSE AGREEMENT”), effective the 3rd day of September, 2008 (which is the date this AMENDMENT NO. 2 has been fully executed by all PARTIES), is made by and between: (1) THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a component institution of SYSTEM; (2) THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (“HJF”), a Maryland tax-exempt corporation, whose address is 1401 Rockville Pike, Suite 600, Rockville, Maryland 20852, on its own behalf and on behalf of THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES (“USU”), an institution of higher learning within the Department of Defense, an agency of
Text Marked By [* * *] Has Been Omitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities And Exchange Commission. AMENDMENT NO. 5 TO THE PATENT AND TECHNOLOGY LICENSE AGREEMENTLicense Agreement • August 15th, 2011 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations
This AMENDMENT NO. 5 to the PATENT AND TECHNOLOGY LICENSE AGREEMENT between the PARTIES dated September 11, 2006, as amended on December 21, 2007, September 3, 2008, July 8, 2009, and February 11, 2010 (the “LICENSE AGREEMENT”), effective the 10th day of January, 2011 (“AMENDMENT NO. 5 EFFECTIVE DATE”, which is the date this AMENDMENT NO. 5 has been fully executed by all PARTIES), is made by and between: (1) THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a member institution of SYSTEM; (2) THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (“HJF”), a Maryland tax-exempt corporation, whose address is 1401 Rockville Pike, Suite 600, Rockville, Maryland 20852, on its own behalf and on behalf of THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES (“USU”), an i
Form of] Amendment to Stock Options Granted Under RXi Pharmaceuticals Corporation 2007 Incentive PlanRxi Pharmaceuticals Corp • August 15th, 2011 • Pharmaceutical preparations
This Amendment to Stock Options, dated as of April __, 2011, is made between RXi Pharmaceuticals Corporation, a Delaware corporation (the “Company”) and the undersigned (the “Holder”).
Text Marked By [* * *] Has Been Omitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities And Exchange Commission. AMENDMENT NO. 4 TO THE PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • August 15th, 2011 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations
This AMENDMENT NO. 4 to the Exclusive PATENT AND TECHNOLOGY LICENSE AGREEMENT between the PARTIES dated September 11, 2006, as amended on December 21, 2007, September 3, 2008, and again on July 8, 2009 (the “LICENSE AGREEMENT”), effective the 11th day of February, 2010 (which is the date this AMENDMENT NO. 4 has been fully executed by all PARTIES), is made by and between: (1) THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a member institution of SYSTEM; (2) THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (“HJF”), a Maryland tax-exempt corporation, whose address is 1401 Rockville Pike, Suite 600, Rockville, Maryland 20852, on its own behalf and on behalf of THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES (“USU”), an institution of higher learning wit
AMENDMENT NO. 3 TO THE PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • August 15th, 2011 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations
This AMENDMENT NO. 3 to the Exclusive PATENT AND TECHNOLOGY LICENSE AGREEMENT between the PARTIES dated September 11, 2006, as amended on December 21, 2007 and September 3, 2008 (the “LICENSE AGREEMENT”), effective the 8th day of July, 2009 (which is the date this AMENDMENT NO. 3 has been fully executed by all PARTIES), is made by and between: (1) THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a component institution of SYSTEM; (2) THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (“HJF”), a Maryland tax-exempt corporation, whose address is 1401 Rockville Pike, Suite 600, Rockville, Maryland 20852, on its own behalf and on behalf of THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES (“USU”), an institution of higher learning within the Department of Defe
